VALISONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VALISONE (VALISONE).
Betamethasone valerate is a corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), which control the release of arachidonic acid from membrane phospholipids, thereby inhibiting prostaglandin and leukotriene synthesis. It has anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Betamethasone valerate is metabolized primarily in the liver via CYP3A4 to its active metabolite, betamethasone. Further metabolism includes reduction and conjugation. |
| Excretion | Renal (primarily as metabolites, <5% unchanged); biliary/fecal elimination accounts for <10%. |
| Half-life | Approximately 1.7 hours after topical application; systemic half-life is short due to rapid metabolism. |
| Protein binding | Approximately 90% bound to plasma proteins. |
| Volume of Distribution | Not well defined for topical use; negligible systemic distribution due to low percutaneous absorption. |
| Bioavailability | Topical: <1% systemic bioavailability with intact skin; higher with damaged skin or occlusion. |
| Onset of Action | Topical: measurable vasoconstriction within 2-3 hours; clinical improvement in 24-48 hours. |
| Duration of Action | Topical: once-daily application maintains effect for 24 hours; systemic effects minimal. |
| Molecular Weight | 521.4 |
Topical: Apply a thin layer to affected skin once or twice daily. Maximum duration: 2 weeks.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Not recommended for children under 12 years due to higher systemic absorption. |
| Geriatric use | Use with caution, apply minimal amounts for shortest duration due to increased risk of skin atrophy and systemic effects. |
| 1st trimester | Risk from topical corticosteroids cannot be ruled out. Use only if potential benefit justifies potential risk to the fetus. Animal studies have shown teratogenicity with high doses. |
| 2nd trimester | Limited data; avoid prolonged or widespread use. Consider risk-benefit. |
| 3rd trimester | Avoid heavy or prolonged use in late pregnancy; may cause fetal adrenal suppression or low birth weight. |
Clinical note
Comprehensive clinical and safety monograph for VALISONE (VALISONE).
| Placental transfer | Systemically absorbed corticosteroids cross the placenta. Degree increases with higher potency, larger surface area, and occlusive use. |
| Breastfeeding | Topical application to small areas is likely safe if used sparingly and not on breast or nipple areas. Avoid large areas or occlusive dressings to reduce infant exposure. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to betamethasone or any componentUntreated bacterial, fungal, or viral skin infectionsPerioral dermatitisRosacea
| Precautions | Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria., Use with caution in pediatric patients as they may absorb proportionally larger amounts due to higher skin surface-to-body weight ratio., Avoid use on face, groin, or axillae unless directed by physician; avoid prolonged use or occlusive dressings., Local adverse reactions include skin atrophy, striae, telangiectasias, purpura, and secondary infection. |
| Food/Dietary | No significant systemic food interactions due to topical administration; however, avoid concurrent use of oral corticosteroids without medical supervision. |
Loading safety data…
| Lactation Rating | L2 - Safer (limited absorption unlikely to cause adverse effects in infant when used appropriately) |
| Teratogenic Risk | Topical corticosteroids, including betamethasone valerate (Valisone), are considered to have a low risk of teratogenicity when used topically in recommended doses. However, systemic exposure can occur, especially with prolonged use on large areas, occluded skin, or damaged skin. In pregnancy, topical corticosteroids are classified as Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second and third trimesters: Use only if clearly needed; avoid chronic high-dose or widespread use. Animal studies show corticosteroids can cause cleft palate and growth retardation at high systemic doses. |
| Fetal Monitoring | Monitor for signs of hypothalamic-pituitary-adrenal (HPA) axis suppression in mother if large areas or occlusive dressings are used. For prolonged therapy or high doses, consider fetal growth monitoring via ultrasound. No specific fetal monitoring is required for short-term, low-dose topical use. |
| Fertility Effects | No direct studies on betamethasone valerate and human fertility. Systemic corticosteroids at high doses may affect fertility by altering hormone levels, but topical use is unlikely to impact fertility at recommended doses. |
| Clinical Pearls | Valisone (betamethasone valerate) is a medium-potency topical corticosteroid. Apply sparingly to thin skin areas (face, flexures) and avoid prolonged use to prevent atrophy. Not for use on infected lesions unless combined with an antimicrobial. |
| Patient Advice | Use only as directed; do not apply to large areas for extended periods. · Avoid contact with eyes and mucous membranes. · Do not cover with bandages unless instructed by your doctor. · Do not use for diaper rash or on broken skin. · Report any signs of skin thinning, discoloration, or infection to your healthcare provider. |